Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults: a network meta-analysis

References

• Globocaniarc.fr [webpage on the Internet]GLOBOCAN 2018: estimated cancer incidence, mortality and prevalence worldwide in 2018 Available from: http://gco.iarc.fr/today/online-analysis-tableAccessed October 17, 2018
   Google Scholar
• EichenauerDAAlemanBMPAndréMESMO Guidelines CommitteeHodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201829Suppl 4iv19iv2929796651
   PubMed Web of Science ®Google Scholar
• CanellosGPRosenbergSAFriedbergJWListerTADevitaVTTreatment of Hodgkin lymphoma: a 50-year perspectiveJ Clin Oncol201432316316824441526
   PubMed Web of Science ®Google Scholar
• HoppeRTAdvaniRHAiWZHodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in OncologyJ Natl Compr Canc Netw201715560863828476741
   PubMed Web of Science ®Google Scholar
• EngertAABVD or BEACOPP for Advanced Hodgkin LymphomaJ Clin Oncol201634111167116926712223
   PubMed Web of Science ®Google Scholar
• BonadonnaGBonfanteVVivianiSDi RussoAVillaniFValagussaPABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term resultsJ Clin Oncol200422142835284115199092
   PubMed Web of Science ®Google Scholar
• LongoDLTreatment of advanced Hodgkin lymphoma: the more things change, the more they stay the sameJ Clin Oncol201331666066223182992
   PubMed Web of Science ®Google Scholar
• CanellosGPAndersonJRPropertKJChemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVDN Engl J Med199232721147814841383821
   PubMed Web of Science ®Google Scholar
• VivianiSZinzaniPLRambaldiAMichelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano LinfomiABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is plannedN Engl J Med2011365320321221774708
   PubMed Web of Science ®Google Scholar
• YounesAConnorsJMParkSIBrentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation studyLancet Oncol201314131348135624239220
   PubMed Web of Science ®Google Scholar
• ConnorsJMJurczakWStrausDJECHELON-1 Study GroupBrentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s LymphomaN Engl J Med2018378433134429224502
   PubMed Web of Science ®Google Scholar
• SkoetzNTrelleSRanceaMEffect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysisLancet Oncol2013141094395223948348
   PubMed Web of Science ®Google Scholar
• SalantiGHigginsJPAdesAEIoannidisJPEvaluation of networks of randomized trialsStat Methods Med Res200817327930117925316
   PubMed Web of Science ®Google Scholar
• CaldwellDMAdesAEHigginsJPTSimultaneous comparison of multiple treatments: combining direct and indirect evidenceBMJ2005331752189790016223826
   PubMed Web of Science ®Google Scholar
• LuGAdesAECombination of direct and indirect evidence in mixed treatment comparisonsStat Med200423203105312415449338
   PubMed Web of Science ®Google Scholar
• HuttonBSalantiGCaldwellDMThe PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanationsAnn Intern Med20151621177778426030634
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGotzschePCCochrane Bias Methods Group; Cochrane Statistical Methods GroupThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• ZhouZRZhangTSLiBMaoZZengXTLiuSX[Extracting and transforming of appropriate data of meta-analysis in survival curve] Shěngcún qǔ xiàn zhōng meta fēnxī shìyí shùjù de tíqú yǔ zhuǎnhuànChin J Evid Based Cardiovasc Med20146243247 Chinese
   Google Scholar
• SalantiGAdesAEIoannidisJPGraphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorialJ Clin Epidemiol201164216317120688472
   PubMed Web of Science ®Google Scholar
• BallovaVRüfferJUHaverkampHA prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)Ann Oncol200516112413115598949
   PubMed Web of Science ®Google Scholar
• GlickJHYoungMLHarringtonDMOPP/ABV hybrid chemotherapy for advanced Hodgkin’s disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trialJ Clin Oncol199816119269440718
   PubMed Web of Science ®Google Scholar
• HoskinPJLowryLHorwichARandomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin’s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244J Clin Oncol200927325390539619738111
   PubMed Web of Science ®Google Scholar
• DiehlVFranklinJPfreundschuhMGerman Hodgkin’s Lymphoma Study GroupStandard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s diseaseN Engl J Med2003348242386239512802024
   PubMed Web of Science ®Google Scholar
• FedericoMLuminariSIannittoEHD2000 Gruppo Italiano per lo Studio dei Linfomi TrialABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi TrialJ Clin Oncol200927580581119124807
   PubMed Web of Science ®Google Scholar
• ChisesiTBelleiMLuminariSLong-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study from the Intergruppo Italiano LinfomiJ Clin Oncol201129324227423321990405
   PubMed Web of Science ®Google Scholar
• MerliFLuminariSGobbiPGLong-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana LinfomiJ Clin Oncol201634111175118126712220
   PubMed Web of Science ®Google Scholar
• DugganDBPetroniGRJohnsonJLRandomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trialJ Clin Oncol200321460761412586796
   PubMed Web of Science ®Google Scholar
• GordonLIHongFFisherRIRandomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)J Clin Oncol201331668469123182987
   PubMed Web of Science ®Google Scholar
• EngertAHaverkampHKobeCGerman Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse TumortherapieReduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialLancet201237998281791179922480758
   PubMed Web of Science ®Google Scholar
• ConnorsJMKlimoPAdamsGTreatment of advanced Hodgkin’s disease with chemotherapy–comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials groupJ Clin Oncol1997154163816459193364
   PubMed Web of Science ®Google Scholar
• MounierNBricePBolognaSLymphoma Study Association (LYSA)ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trialAnn Oncol20142581622162824827123
   PubMed Web of Science ®Google Scholar
• CardePKarraschMFortpiedCEight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOP-Pbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup TrialJ Clin Oncol201634172028203627114593
   PubMed Web of Science ®Google Scholar
• BorchmannPHaverkampHDiehlVEight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEA-COPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study GroupJ Clin Oncol201129324234424221990399
   PubMed Web of Science ®Google Scholar
• EngertADiehlVFranklinJEscalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 studyJ Clin Oncol200927274548455419704068
   PubMed Web of Science ®Google Scholar
• DiehlVSieberMRüfferUBEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. The German Hodgkin’s Lymphoma Study GroupAnn Oncol1997821431489093722
   PubMed Web of Science ®Google Scholar
• The European Medicines AgencyAdcetris (brentuximab vedotin)EU summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdfAcsessed August 6, 2018
   Google Scholar
• CanellosGPDugganDJohnsonJNiedzwieckiDHow important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?J Clin Oncol20042281532153315084636
   PubMed Web of Science ®Google Scholar
• MartinWGRistowKMHabermannTMColganJPWitzigTEAnsellSMBleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphomaJ Clin Oncol200523307614762016186594
   PubMed Web of Science ®Google Scholar